Modality
mRNA
MOA
Anti-Aβ
Target
BCMA
Pathway
Proteasome
RSVHCCFTD
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
Jan 2018
→ Nov 2028
Phase 3Current
NCT07544494
2,061 pts·FTD
2018-01→2028-11·Recruiting
2,061 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-042.6y awayPh3 Readout· FTD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Recruit…
Catalysts
Ph3 Readout
2028-11-04 · 2.6y away
FTD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07544494 | Phase 3 | FTD | Recruiting | 2061 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |